Dr. Theresa A. Guise is Professor, Department of Endocrine Neoplasia and Hormonal Disorders, Chief, Section of Bone and Mineral Disorders at The University of Texas MD Anderson Cancer Center, Cancer Prevention Research Institute of Texas (CPRIT) Scholar and Co-Director of the Rolanette and Berdon Lawrence Bone Disease Program of Texas. She directs a basic, translational and clinical research program on the effects of cancer and cancer treatment on bone, muscle and metabolism. Dr. Guise obtained her M.D. and Internal Medicine Residency Training from the University of Pittsburgh and completed an Endocrinology Fellowship at the University of Texas. Dr. Guise held the Jerry and Peggy Throgmartin Professor of Oncology at the Indiana School of Medicine, the Gerald D. Aurbach Professor of Endocrinology, at the University of Virginia and the Zachry Chair for Translational Research at the University of Texas. She was elected to the American Society for Clinical Investigation (ASCI), the Association of American Physicians (AAP) and chaired the NIH study section of Skeletal Biology, Structure and Regeneration.  Dr. Guise served on the Council of ASBMR, ASCI and International Bone and Mineral Society (IBMS), and as Associate Editor of the Journal of Bone and Mineral Research of ASBMR, Treasurer of ASCI, President of IBMS and Scholar of Susan Komen Foundation. She currently Chairs the Tumor Microenvironment Steering Committee of the American Association for Cancer Research (AACR). Recognitions include the Fuller Albright Award and the Paula Stern Achievement Award from the ASBMR, the Outstanding Investigator Award from the International Bone and Calcium Institute, election to the ASCI and the AAP, Philip S. Hench Award Distinguished Alumnus Award and Legacy Laureate Award from the University of Pittsburgh School of Medicine and Established Investigator and Scholar of CPRIT. Dr. Guise is currently principal investigator in several grant-funded research projects from the NIH, the Department of Defense and CPRIT. Her laboratory has been consistently funded by the NIH, DOD (breast cancer, prostate cancer and neurofibromatosis) as well as by Susan G. Komen, Prostate Cancer Foundation, V-Foundation, Mary K. Ash, pharmaceutical companies and philanthropy.

Lecture Detail:

Bone metastases are common in advanced cancers of breast, prostate, lung, renal, and cause significant morbidity such as bone pain, fracture, hypercalcemia, nerve compression syndromes and muscle weakness. Tumor-bone interactions which result in pathologic bone destruction mediate these well-recognized morbidities. Local events in the bone microenvironment due to cancer and cancer treatment which result in pathologic bone destruction may have wide-spread systemic consequences that further increase morbidity and mortality. Potential mechanisms and therapy will be discussed.